Suppr超能文献

原发性手术切除与肝移植治疗适合移植的肝细胞癌患者。

Primary surgical resection versus liver transplantation for transplant-eligible hepatocellular carcinoma patients.

机构信息

Liver Transplant Program, Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, 750 Welch Road, Suite 210, Palo Alto, CA, 94304, USA,

出版信息

Dig Dis Sci. 2014 Jan;59(1):183-91. doi: 10.1007/s10620-013-2947-8. Epub 2013 Nov 27.

Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) is a leading cause of mortality worldwide. Existing studies comparing outcomes after liver transplantation (LT) versus surgical resection among transplant-eligible patients are conflicting.

AIM

The purpose of this study was to compare long-term survival between consecutive transplant-eligible HCC patients treated with resection versus LT.

METHODS

The present retrospective matched case cohort study compares long-term survival outcomes between consecutive transplant-eligible HCC patients treated with resection versus LT using intention-to-treat (ITT) and as-treated models. Resection patients were matched to LT patients by age, sex, and etiology of HCC in a 1:2 ratio.

RESULTS

The study included 171 patients (57 resection and 114 LT). Resection patients had greater post-treatment tumor recurrence (43.9 vs. 12.9 %, p < 0.001) compared to LT patients. In the as-treated model of the pre-model for end stage liver disease (MELD) era, LT patients had significantly better 5-year survival compared to resection patients (100 vs. 69.5 %, p = 0.04), but no difference was seen in the ITT model. In the multivariate Cox proportional hazards model, inclusive of age, sex, ethnicity, tumor stage, and MELD era (pre-MELD vs. post-MELD), treatment with resection was an independent predictor of poorer survival (HR 2.72; 95 % CI, 1.08-6.86).

CONCLUSION

Transplant-eligible HCC patients who received LT had significantly better survival than those treated with resection, suggesting that patients who can successfully remain on LT listing and actually undergo LT have better outcomes.

摘要

背景

肝细胞癌(HCC)是全球范围内导致死亡的主要原因。现有研究比较了适合移植的患者接受肝移植(LT)与手术切除的结果,结果存在争议。

目的

本研究旨在比较连续适合移植的 HCC 患者接受切除与 LT 的长期生存情况。

方法

本回顾性匹配病例队列研究采用意向治疗(ITT)和实际治疗模型比较了连续适合移植的 HCC 患者接受切除与 LT 的长期生存结果。将切除患者与 LT 患者按年龄、性别和 HCC 病因以 1:2 的比例进行匹配。

结果

本研究纳入了 171 名患者(57 名切除患者和 114 名 LT 患者)。与 LT 患者相比,切除患者治疗后肿瘤复发的比例更高(43.9% vs. 12.9%,p<0.001)。在 MELD 前模型的实际治疗模型中,LT 患者的 5 年生存率明显优于切除患者(100% vs. 69.5%,p=0.04),但在 ITT 模型中没有差异。在包括年龄、性别、种族、肿瘤分期和 MELD 时期(MELD 前 vs. MELD 后)的多变量 Cox 比例风险模型中,切除治疗是生存较差的独立预测因素(HR 2.72;95%CI,1.08-6.86)。

结论

接受 LT 的适合移植的 HCC 患者的生存率明显高于接受切除治疗的患者,这表明能够成功留在 LT 名单上并实际接受 LT 的患者有更好的结局。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验